NASDAQ · STOCK
Edwards Lifesciences
$86.03
52W $72.30 – $96.29
50/100
$49.56B
49.5
0.85
Is EW Bullish or Bearish?
Mixed.
Innellis AI committee rates Edwards Lifesciences (EW) Watch with a composite score of 50/100
, based on 7 analysts with 57% agreement.
Last updated July 31, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +9.98 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -10.02 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. News Analyst sees a compelling case. Value Analyst remains cautious — p/e of 49.4 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Low leverage (debt-to-equity 0.06) -- balance sheet can absorb a shock — Risk
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- P/E of 49.4 is expensive by classic value standards — Value
- Price-to-book of 4.8x prices in significant intangible value — Value
- EPS declining -75.2% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 19.5% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of July 31, 2026
Overall Committee Score
50/100
Agreement
57%
Analysts
7
Conviction
Contested
Sector Rank
Top 87%
of 93 Healthcare peers
Value Analyst
bearish
40
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 49.4 is expensive by classic value standards
Growth Analyst
bearish
40
/ 100 · High confidence
Growth story is weak, decelerating, or inconsistent
− EPS declining -75.2% YoY despite any revenue growth
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.06) -- balance sheet can absorb a shock
− Bollinger bandwidth of 19.5% signals elevated volatility
Macro Analyst
neutral
58
/ 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Investment Thesis Evolution
Committee score moved marginally from 51.1 to 50.0.
- Committee agreement increased notably from 43% to 57%.
- New bearish signals: 3 appeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 3 signal(s) disappeared.
- Analyst(s) changed stance: Macro Analyst.
Analyst-level changes:
- Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
- Portfolio Manager: +2 bearish signal(s).
- Risk Analyst: +1 bearish signal(s).
Comparing 2026-07-30 to 2026-07-31 (1 day apart).
Technical Analysis
RSI (14)
49.9
Neutral
MACD Histogram
-0.182
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$85.58
Resistance
$86.98
Bollinger %B
0.39
Inside Bands
Price vs Moving Averages
EMA 9
$85.52
Above
EMA 21
$86.62
Below
EMA 50
$86.65
Below
EMA 200
$83.46
Above
Fundamental Analysis
Valuation
50
Growth
60
Profitability
1
Financial Health
100
Cash Flow
37
Valuation
P/E Ratio
49.5×
P/B Ratio
4.80×
PEG Ratio
-0.66
Dividend Yield
0.00%
52W High
$96.29
52W Low
$72.30
Quality & Growth
ROE
10.4%
ROA
7.8%
Gross Margin
78.0%
Operating Margin
28.1%
Revenue Growth YoY
—
Debt / Equity
0.07
AI Fundamental Assessment
P/E ratio of 49.5 (rich relative to a 15-40x range); Price-to-book of 4.8x; PEG ratio of -0.7 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.1%; Return on assets of 0.1%; Net margin of 0.2%; Gross margin of 0.8%; Current ratio of 4.42 (healthy short-term liquidity); Debt-to-equity of 0.07; Free cash flow margin of 0.8% (thin cash generation); Free cash flow per share is positive (1.89); Most recent quarter beat estimates by 2.1%; 2 consecutive earnings beats; EPS growth decelerating (+34.5% -> +0.0% QoQ); Average YoY EPS growth of 16.4%; Analyst estimates rising over recent quarters
Get the Full EW Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →